Early cancer drug trial focuses on patients with compromised livers
NCT ID NCT05661461
Summary
This early-stage study aims to find a safe dose of the drug nab-sirolimus for adults with advanced solid tumors who also have moderate liver problems. It will compare how the drug is processed in the body between these patients and those with normal liver function. The main goal is to understand safety and determine the right dose for future research in this specific patient group.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
START Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
Contact
Contact Email: •••••@•••••
-
South Texas Accelerated Research Therapeutics, LLC
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.